MADADI PRGNYA

Pragnya Madadi is a biotechnology company focused on the early-stage research and development of small molecule therapeutics, primarily for oncology indications. The company utilizes a combination of computational modeling and medicinal chemistry to target epigenetic and structural proteins involved in tumor progression. Its research portfolio includes the development of histone deacetylase (HDAC) inhibitors and tubulin polymerization inhibitors aimed at treating solid tumors such as breast and lung cancer. Based in Hyderabad, India, the firm operates as a specialized R&D entity dedicated to discovering novel chemical entities with improved pharmacological profiles. Pragnya Madadi is currently in the preclinical stage of development for its lead programs.